On The Pen GLP-1 News

Dave Knapp GLP-1 Industry Insider

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

About PodLP

PodLP is the leading podcast app for feature phones. With 10M+ installs in nearly every country, PodLP is available for KaiOS on the KaiStore and JioStore, as well as Cloud Phone and Android. If you're interested in promoting "On The Pen GLP-1 News" on PodLP, contact sales@podlp.com.

Screenshots are mockup renders of PodLP for KaiOS. Actual design may vary based on platform, operating system, and app version.

On The Pen GLP-1 News

Episodes (181)

Thursday Zepbound Dosing: What Your Doctor Didn't Explain
Mar 31st Wegovy Price Drop Exposes a Bigger Problem
Mar 24th Retatrutide Is Too Good… And That’s The Problem

On The Pen GLP-1 News

Apr 2, 2026
1½ hours
67 MB

Are you on tirzepatide or semaglutide and struggled with inconsistent weight loss and side effects? On this episode of On The Pen, Dave Knapp and Dr. Ian Ellis dive into the surprising variability of GLP-1 dosing (retatrutide, tirzepatide), even when the weekly dose remains the same. We explore how these subtle dosage changes can lead to frustrating glp-1 side effects and why many individuals eventually give up on their weight loss medication. This new way of thinking about glp-1 dosing could change the obesity medicine game. Referenced Links: http://www.OTPLinks.com00:00 Why most GLP-1 users are never on...

On The Pen GLP-1 News

Zepbound Dosing: What Your Doctor Didn't Explain

Dave Knapp GLP-1 Industry Insider

00:00 -01:13:34